In support of such a role, exogenous administration of estrogen and progestin during the development of CRC in postmenopausal woman has been reported in several studies [31], and this phenomenon could be explained, as we hypothesize here, by a negative feedback of these hormones on PtG release, including of FSH [32]. This evidence concerns the gene BRD2 and colorectal carcinoma.